Cleviprex Generic Name & Formulations
Legal Class
Rx
General Description
Clevidipine butyrate emulsion 0.5mg/mL; soln for IV infusion; contains lipids 0.2g/mL (soybean oil, egg phospholipids).
Pharmacological Class
Calcium channel blocker (CCB) (dihydropyridine).
How Supplied
Single-use vials (50mL, 100mL)—10
Manufacturer
Generic Availability
NO
Cleviprex Indications
Indications
To reduce blood pressure when oral therapy is not feasible or desirable.
Cleviprex Dosage and Administration
Adult
≥18yrs: Individualize; titrate. Give by IV infusion. Initially 1–2mg/hr; double dose at 90sec intervals until BP approaches goal, then titrate slower (adjust at 5–10min intervals). Dose increases of 1–2mg/hr results in systolic BP lowering of about 2–4mmHg. Maintenance: 4–6mg/hr; usual max 16–32mg/hr. Do not exceed 1000mL (21mg/hr for 24hrs) due to lipid load. Switch to oral therapy when indicated.
Children
<18yrs: not established.
Cleviprex Contraindications
Contraindications
Egg or soy allergy. Defective lipid metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia). Severe aortic stenosis.
Cleviprex Boxed Warnings
Not Applicable
Cleviprex Warnings/Precautions
Warnings/Precautions
Maintain aseptic technique. Monitor BP and pulse during infusion and until stabilized. Heart failure (monitor). Monitor for rebound hypertension for at least 8hrs after stopping infusion (if not given other antihypertensives after prolonged infusion). Avoid abrupt cessation of any β-blocker treatment. Pheochromocytoma. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Cleviprex Pharmacokinetics
See Literature
Cleviprex Interactions
Not Applicable
Cleviprex Adverse Reactions
Adverse Reactions
Headache, nausea, vomiting; hypotension, reflex tachycardia (slow infusion if occurs, do not use beta-blocker); rare: myocardial infarction, cardiac arrest, syncope, dyspnea.
Cleviprex Clinical Trials
See Literature
Cleviprex Note
Not Applicable
Cleviprex Patient Counseling
See Literature
Images
